AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31430616 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral osteopathic technique
Number of subjects: 94
Study 31430616 — intervention group
Group type: COMPARATOR
Intervention: Superficial manipulation (placebo)
Number of subjects: 94
Study 29897866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Number of subjects: 7447
Study 29897866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 7447
Study 29897866 — intervention group
Group type: COMPARATOR
Intervention: Control diet (advice to reduce dietary fat)
Number of subjects: 7447
Study 26768569 — intervention group
Group type: COMPARATOR
Intervention: Various treatment alternatives for Ebola virus, including repurposed drugs; specific dosages and durations not mentioned.
Number of subjects: 0
Study 25200552 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of vitamin D3 (250,000 IU) followed by oral maintenance vitamin D3/calcium (800 IU/500 mg)
Number of subjects: 218
Study 25200552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 22451449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 0
Study 22451449 — intervention group
Group type: COMPARATOR
Intervention: Lesser coronary plaque regression
Number of subjects: 0
Study 22451449 — intervention group
Group type: COMPARATOR
Intervention: Greater coronary plaque regression
Number of subjects: 0
Study 21162726 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR)
Number of subjects: 100
Study 21162726 — intervention group
Group type: COMPARATOR
Intervention: Stabilization Exercise (SE)
Number of subjects: 100
Study 17329285 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group exercise
Number of subjects: 32
Study 17329285 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised home exercise
Number of subjects: 32
Study 15642910 — intervention group
Group type: EXPERIMENTAL
Intervention: AN1792 (50 or 225 microg) with QS‐21 adjuvant (50 or 100 microg)
Number of subjects: 80
Study 15642910 — intervention group
Group type: EXPERIMENTAL
Intervention: AN1792 + QS‐21
Number of subjects: 80
Study 15642910 — intervention group
Group type: COMPARATOR
Intervention: QS‐21 only (control)
Number of subjects: 80
Study 11907497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 403
Study 11907497 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 403
Study 9800141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.25 g/kg)
Number of subjects: 11
Study 9800141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30% N2O in oxygen)
Number of subjects: 11
Study 9800141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol and Nitrous oxide (combination)
Number of subjects: 11
Study 9800141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100% oxygen)
Number of subjects: 11
Study 8777409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 10 mg moxisylyte
Number of subjects: 307
Study 8777409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 2178693 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline
Number of subjects: 10
Study 2178693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6107678 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis retinoic acid (0.1 mg‐1.0 mg/kg body‐weight)
Number of subjects: 0
Study 31304536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp 750 mg
Number of subjects: 27
Study 31304536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp 500 mg
Number of subjects: 27
Study 31304536 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (SOC)
Number of subjects: 27
Study 31304536 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (continued therapy)
Number of subjects: 27
Study 27845219 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose tadalafil (5 mg)
Number of subjects: 96
Study 27845219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 25877748 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy after gefitinib
Number of subjects: 71
Study 24219098 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% lavender oil
Number of subjects: 64
Study 24219098 — intervention group
Group type: COMPARATOR
Intervention: Inactive control oil
Number of subjects: 64
Study 21219593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone-supported cognitive behavioural therapy (CBT) for anxiety disorders; specific dosage and duration not mentioned.
Number of subjects: 0
Study 19203298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 603
Study 19203298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Number of subjects: 603
Study 19203298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 100 mg
Number of subjects: 603
Study 19203298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl IR 15 mg
Number of subjects: 603
Study 19203298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 17893579 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter general anesthesia (propofol 2 mug/mL and rimifentanil 2 ng/mL)
Number of subjects: 50
Study 17893579 — intervention group
Group type: COMPARATOR
Intervention: Control group (propofol 4 microg/mL and rimifentanil 4 ng/mL)
Number of subjects: 50
Study 15591955 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term cyclosporine followed by azathioprine and prednisolone (CyAP)
Number of subjects: 489
Study 15591955 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cyclosporine alone (Cy)
Number of subjects: 489
Study 15591955 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine and prednisolone alone (AP)
Number of subjects: 489
Study 11419519 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention alone
Number of subjects: 646
Study 11419519 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in the presence of a significant other
Number of subjects: 646
Study 11419519 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 646
Study 15321210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 9.375 mg (15 ml of 0.0625%) with fentanyl 37.5 microg and adrenaline 37.5 microg
Number of subjects: 0
Study 15321210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg (15 ml of 0.1%) with fentanyl 30 microg and adrenaline 30 microg
Number of subjects: 0
Study 15321210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 10 mg (4 ml of 0.25% ‐ test) followed by bupivacaine 20 mg (8 ml of 0.25% ‐ loading)
Number of subjects: 0
Study 7943835 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 8% (1.1 MAC) for 10 min after an initial increase from 4%
Number of subjects: 9
Study 7943835 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent increases in desflurane concentration
Number of subjects: 9
Study 7943835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar nerve stimulation
Number of subjects: 9
Study 7943835 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with 60% nitrous oxide
Number of subjects: 9
Study 3508193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nippon Colin BP-103N blood pressure monitor
Number of subjects: 0
Study 3508193 — intervention group
Group type: COMPARATOR
Intervention: Hawksley random zero mercury sphygmomanometer
Number of subjects: 0
Study 29266092 — intervention group
Group type: EXPERIMENTAL
Intervention: FEDWASH (30 g CHO·h during SS + WASH during TT)
Number of subjects: 10
Study 29266092 — intervention group
Group type: COMPARATOR
Intervention: FEDPLA (30 g CHO·h during SS + placebo wash during TT)
Number of subjects: 10
Study 28419170 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based cognitive behaviour therapy (CBT)
Number of subjects: 83
Study 28419170 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one cognitive behaviour therapy (CBT)
Number of subjects: 83
Study 28419170 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 83
Study 25185593 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 150
Study 25185593 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-buffered balanced crystalloid
Number of subjects: 150
Study 23974823 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant TMZ (75 mg/m²/day) during the first and last weeks of RT in the RT-TMZ-10.00 study
Number of subjects: 104
Study 23974823 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant TMZ (75 mg/m²/day) during all weeks of RT in the RT-TMZ-01.04 trial
Number of subjects: 104
Study 23974823 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant TMZ (200 mg/m²) administered for 5 days every 28 days
Number of subjects: 104
Study 23974823 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment regimens (implied control)
Number of subjects: 104
Study 20670755 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 427
Study 20670755 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 427
Study 19092151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1050
Study 19092151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study 15990745 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic) 1000 microg daily for 3 months
Number of subjects: 60
Study 15990745 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the first 3 months, then CrPic for the next 3 months
Number of subjects: 60
Study 12848714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth gingival transplantation (TGT)
Number of subjects: 76
Study 12848714 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (tooth with periodontal ligament)
Number of subjects: 76
Study 10778590 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegretol 200
Number of subjects: 12
Study 10778590 — intervention group
Group type: COMPARATOR
Intervention: Zen‐200
Number of subjects: 12
Study 8720373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1.8 g of n-3 PUFA)
Number of subjects: 37
Study 8720373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 37
Study 2036564 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 350
Number of subjects: 0
Study 2036564 — intervention group
Group type: EXPERIMENTAL
Intervention: Niopam 370
Number of subjects: 0
Study 2036564 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 300
Number of subjects: 0
Study 2036564 — intervention group
Group type: EXPERIMENTAL
Intervention: Niopam 300
Number of subjects: 0
Study 2036564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultravist 300
Number of subjects: 0
Study 2036564 — intervention group
Group type: COMPARATOR
Intervention: Diluted media (150 mgI/ml)
Number of subjects: 0
Study 2036564 — intervention group
Group type: COMPARATOR
Intervention: All 300 strength contrast media diluted to 150 strength
Number of subjects: 0
Study 7055525 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural morphine (4mg before skin incision and an additional 4mg at skin closure)
Number of subjects: 36
Study 7055525 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (halothane) plus systemic opiates
Number of subjects: 36
Study 7055525 — intervention group
Group type: COMPARATOR
Intervention: Continuous extradural analgesia with bupivacaine
Number of subjects: 36
Study 31734419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane postconditioning (1 minimum alveolar concentration for 15 minutes after reperfusion)
Number of subjects: 152
Study 31734419 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 152
Study 31734419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane postconditioning
Number of subjects: 152
Study 31648461 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI=100% group
Number of subjects: 1829
Study 31648461 — intervention group
Group type: COMPARATOR
Intervention: 50%≤SRI<100% group
Number of subjects: 1829
Study 31648461 — intervention group
Group type: COMPARATOR
Intervention: SRI<50% group
Number of subjects: 1829
Study 31648461 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI<65%
Number of subjects: 1829
Study 31648461 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI=65%
Number of subjects: 1829
Study 28533226 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with concurrent trastuzumab (Arm C)
Number of subjects: 1734
Study 28533226 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Arm A)
Number of subjects: 1734
Study 28533226 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with sequential trastuzumab (Arm B)
Number of subjects: 1734
Study 25643353 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-iodine group (270 mg I/mL, 100 kVp) with iterative reconstruction (IR)
Number of subjects: 100
Study 25643353 — intervention group
Group type: COMPARATOR
Intervention: High-iodine group (370 mg I/mL, 120 kVp)
Number of subjects: 100
Study 25643353 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-iodine group
Number of subjects: 100
Study 22987136 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (group A; 219 patients) - intravenous infusion (15 mg/kg for 48 h postoperatively) after a loading dose (5 mg/kg)
Number of subjects: 438
Study 22987136 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (group M; 219 patients) - loading dose (80 mg/kg over 30 min preoperatively) and then intravenous infusion (8 mg/kg/h for 48 h)
Number of subjects: 438
Study 22987136 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C; 219 patients) - analyzed retrospectively
Number of subjects: 438
Study 21316089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided puncture PCNL
Number of subjects: 131
Study 21316089 — intervention group
Group type: COMPARATOR
Intervention: Doppler ultrasound-guided PCNL
Number of subjects: 131
Study 19635156 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (n = 4)
Number of subjects: 7
Study 19635156 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (n = 3)
Number of subjects: 7
Study 19635156 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept and Cyclosporine
Number of subjects: 7
Study 17523328 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic 2000 (lactobacilli preparations with 10^10 CFU and prebiotics)
Number of subjects: 62
Study 17523328 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic 2000
Number of subjects: 62
Study 17523328 — intervention group
Group type: COMPARATOR
Intervention: Control (only prebiotics)
Number of subjects: 62
Study 15466687 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs presented at the Society for Pediatric Research meetings
Number of subjects: 393
Study 15466687 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpublished RCTs
Number of subjects: 393
Study 11495873 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg po
Number of subjects: 200
Study 11495873 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg po
Number of subjects: 200
Study 9706735 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (doses not specified)
Number of subjects: 0
Study 9706735 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (high doses)
Number of subjects: 0
Study 9706735 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 9706735 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (doses beyond 600 mg/day)
Number of subjects: 0
Study 7817799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride treatment (60 mg NaF/day for 1-2 years)
Number of subjects: 7
Study 7817799 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 7
Study 7817799 — intervention group
Group type: COMPARATOR
Intervention: Osteoporotic bone before fluoride treatment
Number of subjects: 7
Study 3287971 — intervention group
Group type: EXPERIMENTAL
Intervention: cefotetan
Number of subjects: 303
Study 3287971 — intervention group
Group type: EXPERIMENTAL
Intervention: moxalactam
Number of subjects: 303
Study 3287971 — intervention group
Group type: EXPERIMENTAL
Intervention: cefoxitin
Number of subjects: 303
Study 30969209 — intervention group
Group type: EXPERIMENTAL
Intervention: Backfill-assisted void trial (group A)
Number of subjects: 153
Study 30969209 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous voiding trial (group B)
Number of subjects: 153
Study 29339649 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acids (MUFAs) hypocaloric diet (diet M)
Number of subjects: 361
Study 29339649 — intervention group
Group type: COMPARATOR
Intervention: High polyunsaturated fatty acids (PUFAs) hypocaloric diet (diet P)
Number of subjects: 361
Study 25710303 — intervention group
Group type: EXPERIMENTAL
Intervention: New credo aftercare program (12 months duration) for rehabilitation patients with relevant impairments.
Number of subjects: 238
Study 25710303 — intervention group
Group type: EXPERIMENTAL
Intervention: New credo aftercare program (12 months duration) for rehabilitation patients with low impairments.
Number of subjects: 238
Study 25710303 — intervention group
Group type: COMPARATOR
Intervention: Control group without aftercare program.
Number of subjects: 238
Study 24364538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal users
Number of subjects: 412
Study 24364538 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 412
Study 21252208 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized bypass circuit (Group A)
Number of subjects: 80
Study 21252208 — intervention group
Group type: COMPARATOR
Intervention: Standard bypass circuit (Group B)
Number of subjects: 80
Study 18922086 — intervention group
Group type: EXPERIMENTAL
Intervention: pVIS light (385-750 nm)
Number of subjects: 50
Study 18922086 — intervention group
Group type: EXPERIMENTAL
Intervention: pVIS + nIR light (385-1700 nm)
Number of subjects: 50
Study 18922086 — intervention group
Group type: COMPARATOR
Intervention: Control (no light exposure)
Number of subjects: 50
Study 17333787 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, 30 mg/day for 10 days
Number of subjects: 190
Study 17333787 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracentesis to remove fluid
Number of subjects: 190
Study 17333787 — intervention group
Group type: COMPARATOR
Intervention: Anti-tuberculosis (TB) drugs for 6 months
Number of subjects: 190
Study 15125487 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (one ounce, corresponding to two drink equivalents)
Number of subjects: 12
Study 10929163 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate lozenges (12.8 mg)
Number of subjects: 50
Study 8931165 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fenfluramine
Number of subjects: 60
Study 8931165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1396796 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque (iohexol) 350 mgI/ml
Number of subjects: 60
Study 1396796 — intervention group
Group type: COMPARATOR
Intervention: Telebrix (sodium-meglumine-ioxithalamate) 350 mgI/ml
Number of subjects: 60
Study 2861365 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polylactide‐glycolide copolymer implants
Number of subjects: 44
Study 2861365 — intervention group
Group type: COMPARATOR
Intervention: Conventional metallic implants
Number of subjects: 44
Study 30712718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 28
Study 30712718 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 28
Study 28820746 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Cycloserine (125 mg) administered pre-exposure therapy
Number of subjects: 57
Study 28820746 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Cycloserine (125 mg) administered post-exposure therapy
Number of subjects: 57
Study 28820746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 25403903 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months for 3 years
Number of subjects: 810
Study 25403903 — intervention group
Group type: COMPARATOR
Intervention: Denosumab 60 mg subcutaneously every 6 months for 1 year (cross-over group)
Number of subjects: 810
Study 24771706 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist self-monitoring device with daily BP measurement for 24 weeks
Number of subjects: 196
Study 24771706 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study 24771706 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist self-monitoring device
Number of subjects: 196
Study 24771706 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 196
Study 21786110 — intervention group
Group type: EXPERIMENTAL
Intervention: MV-CBCT (megavolt cone-beam CT)
Number of subjects: 9
Study 21786110 — intervention group
Group type: COMPARATOR
Intervention: MV-CBCT (automatic registration)
Number of subjects: 9
Study 21786110 — intervention group
Group type: COMPARATOR
Intervention: MV-CBCT (soft tissue registration)
Number of subjects: 9
Study 19366127 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC loading rhBMP-2
Number of subjects: 112
Study 19366127 — intervention group
Group type: COMPARATOR
Intervention: CPC
Number of subjects: 112
Study 17695700 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 0
Study 14769778 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg 5‐MTHF
Number of subjects: 0
Study 14769778 — intervention group
Group type: COMPARATOR
Intervention: 5 mg folic acid
Number of subjects: 0
Study 12365087 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatment (ACE inhibitor, beta‐blocking drug or ARB)
Number of subjects: 48
Study 12365087 — intervention group
Group type: COMPARATOR
Intervention: Single treatment (calcium channel‐blocking drug or thiazide diuretic)
Number of subjects: 48
Study 12365087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination therapy (one drug from group 1 and one drug from group 2)
Number of subjects: 48